Skip to search formSkip to main contentSkip to account menu

cediranib

Known as: 4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)- 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

AZD2171

Broader (3)

Antineoplastic AgentsProtein Kinase InhibitorsQuinazolines
Cediranib MaleateReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Emerging VEGF-receptor inhibitors for colorectal cancer
Introduction: Targeted agents have dramatically improved and enriched the therapeutical choices for patients with metastatic… 
Review
2011
Review
2011
Antiangiogenic therapies in epithelial ovarian cancer.
BACKGROUND Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been… 
2011
2011
Novel quinazoline HMJ‐30 induces U‐2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up‐regulation of ATM/p53 signaling pathway
Human osteogenic sarcoma is the most common primary bone tumor. Despite of the success of frontline therapy, about 40% of… 
2011
2011
A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics
BackgroundCediranib (RECENTIN™) is an oral, highly potent VEGF inhibitor. This study evaluated the effect of food on the… 
Highly Cited
2010
Highly Cited
2010
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor…
BACKGROUND Hypertension (HTN), a recognized adverse effect of angiogenesis inhibitors, may be a potential biomarker of activity… 
Review
2009
Review
2009
Antiangiogenic strategies for treatment of malignant gliomas
2009
2009
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
e19007 Background: There are only limited data regarding the use of anti-VEGF therapy in recurrent NSCLC and no data in NSCLC pts… 
2008
2008
Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer
5501 Background: Angiogenesis is important for ovarian cancer growth; blocking angiogenesis can lead to ovarian cancer regression… 
2008
2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
5047 Background: Cediranib (AZD2171) is an oral highly potent, selective pan-VEGFR tyrosine kinase inhibitor expected to show… 
2008
2008
A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS…
4028 Background: Cediranib (AZD2171) is an oral, highly potent and selective inhibitor of VEGF signaling, with activity against… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)